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Introduction
Long held as an important, patient-centered approach for evaluating the effectiveness of elective orthopaedic procedures, patient-reported outcome measures (PROMs) are increasingly being recognized for their potential utility in care delivery and the assessment of care quality [21, 23, 25, 34] . The most well-validated joint-specific PROMs for arthroplasty are the Hip Disability and Osteoarthritis Outcomes Survey (HOOS) [28] and the Knee Injury and Osteoarthritis Outcomes Survey (KOOS) [32] . These PROMs along with their short-form versions for joint replacement (HOOS, JR and KOOS, JR, respectively) [16, 17] have been adopted by the Centers for Medicare & Medicaid Services (CMS) in their Comprehensive Care for Joint Replacement (CJR) Model, which is a bundled payment plan for primary elective total joint replacement. As part of this program, for the first time the CMS has incentivized PROM collection [8] . However, meaningful use of PROMs for assessing care delivery and/or care quality requires validated methodologies to measure changes in PROM scores and, based on that, an understanding of how much change over time should be expected and, most importantly, how much change matters to patients. These measures have not yet been established in our professional community.
Various methods can be used to calculate meaningful change in PROM scores such as the minimal detectable change (MDC), minimally clinically important difference (MCID), and substantial clinical benefit [1, 7, 29] . The MDC is the minimal amount of change in a PROM score required to signify a true health change given variability resulting from measurement error inherent in a given PROM [26] . The MCID, also sometimes referred to as the "minimal clinically important improvement," reflects the minimum change in PROM scores that patients can perceive as a change in their health [2, 31, 37] . The substantial clinical benefit is the lower bound for defining optimal patient benefit [12] . Although the definitions are clear, methodology choices can result in wide variability in estimated values [30] . This variability poses a critical challenge, because these values carry important clinical implications; changes in patients' scores that are lower than the MDC should be considered irrelevant. Changes in patients' scores that are lower than the MCID imply treatment failures. Change in patients' scores that fall between the MCID and substantial clinical benefit represent Volume 476, Number 12 Measuring Improvement With HOOS and KOOS 2433 changes that may range between the perceptible and the meaningful, but less than the substantial (depending on how the MCID is anchored in the surveys on which it is based). Only scores that exceed the substantial clinical benefit should be considered completely successful. Using PROMs to inform care decisions, determine the appropriateness of therapeutic choices, and assess health care quality in orthopaedics requires an understanding of which calculations are most reliable and best reflect true improvement in joint-related health. Previous studies have attempted to establish MCID, MCD, and/or substantial clinical benefit for HOOS and KOOS, but their cohorts were not large, and the findings in these studies were not consistent with each other [3, 4, 22, 30, 35] . Validated measures for MCID, MCD, and substantial clinical benefit, which are agreed on by our professional community, are still lacking and needed if we are to be able to use HOOS, KOOS, or their JR versions accurately and fairly for clinical applications.
We therefore investigated our institution's extensive TKA and THA registries (1) to assess the validity of estimates for MCIDs calculated using distribution-and anchor-based methods by determining whether they exceed the MDC for the HOOS and the KOOS domains, the HOOS, JR, and the KOOS, JR among patients who underwent THA or TKA; (2) to determine substantial clinical benefit thresholds for the HOOS and KOOS domains, the HOOS, JR, and the KOOS, JR among patients who underwent THA or TKA; and (3) to assess the proportions of patients who underwent THA or TKA who achieved an MCID for the HOOS and KOOS domains, HOOS, JR, and KOOS, JR based on distribution-based and anchor-based methods as well as the percentages of patients who achieved substantial clinical benefit using the anchor-based method.
Materials and Methods
This retrospective study draws data from a longitudinally maintained institutional registry; the Hospital for Special Surgery (HSS) Joint Replacement Registry includes all consenting patients undergoing THA and TKA between May 2007 and April 2012. Approximately 80% of consented patients completed HOOS or KOOS preoperatively as part of the requirement for inclusion in the registry and were mailed or emailed the same PROMs 2 years after their index surgery. The HOOS and KOOS are self-administered and completed without the aid of the surgeon or other medical staff.
All Medicare patients who met the CJR bundle inclusion criteria and who had completed preoperative and 2-year postoperative PROMs were included in this analysis [8] . Patients were ineligible if they underwent revision or another THA or TKA within 2 years of their index surgery. In terms of data completeness, 78% (3161 of 4080) of THAs and 74% (3815 of 5156) of TKAs consented to join the registry and completed a baseline survey, 88% (2796 of 3161) of THAs and 85% (3230 of 3815) of TKAs were eligible for followup survey administration, and 83% (2323 of 2796) of THAs and 81% (2630 of 3230) of TKAs returned 2-year surveys. All patients underwent a primary, unilateral TKA or THA and reported pre-and postoperative PROMs.
We collected data from responses to the full HOOS and KOOS with all calculable osteoarthritis or total joint replacement-relevant domain scores, including pain, symptoms, activities of daily living (ADL), and quality of life (QOL). The JR versions were calculated from the full HOOS and KOOS. All HOOS and KOOS domains and all JR are scored from 0 (worst joint health) to 100 (best joint health).
In all, 2323 patients who underwent THA and 2630 patients who had TKA met our inclusion criteria. These Medicare patients with complete PROMs were comparable to all primary THA and TKA Medicare patients treated at our institution during the study period who also met criteria for inclusion in the CJR bundle (Table 1) .
Statistical Analysis
We analyzed the HOOS responses from 2323 patients who had THA and the KOOS responses from 2630 patients who underwent TKA. All mean 2-year postoperative HOOS and KOOS scores were compared with the preoperative baseline scores (Table 2) .
Minimal Detectable Change
The MDC is the minimal amount of change required to distinguish a true health change from variability resulting from measurement error; its calculations rely on a distribution-based approach that reflects a correction factor applied to the standard error of measurement (SEM) [26] . We calculated the MDC as follows: MDC = z score x SEM x √2. We evaluated the MDCs z score with confidence intervals (CIs) reflecting 80%, 90%, and 95% certainty. The resulting MDC80, MDC90, and MDC95 correspond to a 5:1, 10:1, and 20:1 likelihood, respectively, of a patient's true PROM score falling outside the reported score. We applied a z score of 1.28 to MDC80, a z score of 1.64 to MDC90, and a z score of 1.96 to MDC95. We calculated SEM values as follows: SEM = SD x √(1 -ICC) with SD representing the SD of the baseline measurement and intraclass correlation coefficient (ICC) from the earlier studies [11, 33] , which had a median reliability of 0.90 across all HOOS/KOOS domains.
Minimal Clinically Important Difference
The MCID, also sometimes referred to as the "minimal clinically important change" or "minimal clinically important improvement," reflects the minimum change in PROM scores that a patient perceives as a change in their health [2, 9, 31, 37] . The MCID can be estimated using at least 14 methods [39] . For this analysis we compared distribution-based and anchor-based receiver operating characteristic (ROC) curve methods [4, 12, 30] . We did not assess consensus methods based on clinician opinions. We reasoned that estimates derived from such methods violate the intent of PROMs: to understand outcomes exclusively from the patient's perspective [24] .
The distribution-based approach assumes a normal response distribution. The calculation most often used is 0.5 x SD of the delta (change from baseline to followup) [4] . The anchor-based approach relies on an anchor question, asked at followup, and distinguishes patients who have had a change in their state of health from those who have not.
For our anchor questions, we selected the QOL satisfaction item from the HSS Satisfaction Survey at 2-year followup ( Fig. 1) because it is joint-specific and has previously been used as an anchor for MCID calculation in TKA [19] .
Then, we used a logistic regression and the area under the ROC curve to find the delta score cut point that best identified which patients experienced a minimal improvement and those who did not according to anchor question responses.
To define minimal improvement for the anchor-based MCID, we considered the difference between those who answered "moderate improvement" (experienced minimal improvement) to those who reported "a little improvement" or "no improvement" (did not experience minimal improvement) on their QOL measure. We combined the little and no improvement groups because the no improvement group was small (Fig. 1) .
Substantial Clinical Benefit
Substantial clinical benefit, which was initially proposed by Glassman et al. [12] to be the lower bound for defining optimal patient benefit, was calculated using the anchorbased ROC approach. Our anchor was again the QOL item from the HSS Satisfaction Survey. We compared those who answered "more improvement than I ever dreamed possible" and "great improvement" with those who reported "a little improvement" or "no improvement." We combined the more and great improvement categories because the mean change for these groups was < 4 out of 100 points across all the evaluated PROM domains. After calculating candidate MDC, MCID, and substantial clinical benefit values for all domains of the HOOS/KOOS and the HOOS/KOOS, JR, we determined how many patients in the cohort achieved these values. Finally, we considered the face validity of the various MDC, MCID, and substantial clinical benefit values based on conceptual frameworks requiring that MDC be less than MCID and that MCID be less than or equal to substantial clinical benefit. We reasoned that an MCID or substantial clinical benefit that was smaller than an MDC, which represents the error of the scoring instrument, should not be considered a valid estimate [36] .
Results

Validity of MCID Estimates
We assessed the validity of estimates for MCIDs calculated using distribution-and anchor-based methods by determining whether they exceeded the MDC for the HOOS, the KOOS, the HOOS, JR, and the KOOS, JR domains among patients who underwent THA or TKA. The MDC varied substantially based on selected CI, ranging from 7 to 16 for each HOOS and KOOS domain and the JR PROMs ( Table 3 ). As Fig. 1 The QOL item from the HSS Satisfaction Survey was used as the anchor question for calculating MCID and substantial clinical benefit, as described in the Materials and Methods. expected, values for the MDC95 were generally approximately 50% greater than those for the MDC80 across all domains for both HOOS and KOOS and the JR versions. The JR versions of the HOOS and the KOOS had smaller MDC values than any of the HOOS/KOOS domains. Across the HOOS/KOOS domains and the JR versions, the MCIDs ranged from 6 to 9 for the distribution-based approach, and they ranged from 7 to 36 for the anchorbased approach.
The MCIDs calculated using the distribution-based approach were smaller than the corresponding MDC80, MDC90, and MDC95 for every domain and each JR version for both the HOOS and the KOOS, indicating that they were not valid ( Table 3) .
The MCIDs calculated using the anchor-based ROC were greater than the corresponding MDC80 and MDC90 for all HOOS domains and the JR versions. The MCIDs were greater than the corresponding MDC95 for the JR version and all HOOS domains except ADL, for which the MDC95 was 16 and the anchor MCID was 14 ( Table 3) .
The MCIDs calculated using the anchor-based ROC were greater than the corresponding MDC80, MDC90, and MDC95 for the JR version and all domains of the KOOS except symptom domain (Table 3) . For this domain, the MCID was smaller than the MDC at every confidence level.
Substantial Clinical Benefit (SCB) Thresholds
We determined thresholds for a substantial clinical benefit for the HOOS and KOOS domains, the HOOS, JR, and the KOOS, JR among patients who underwent THA or TKA. For THA, the substantial clinical benefit ranged from 24 to 36 and exceeded the corresponding MDCs and MCIDs for all HOOS domains and the JR version.
For TKA, the substantial clinical benefit ranged from 15 to 23 across KOOS domains and the JR version. The substantial clinical benefits exceeded the corresponding MDCs and MCIDs for the JR version and all KOOS domains except the ADL domain where the MCID was 16 and the substantial clinical benefit 15 ( Table 3 ). The substantial clinical benefit for the KOOS ADL domain surpassed the MDC80, MDC90, and MDC95.
Proportions of Patients Achieving MCID and SCB
Across the HOOS and the HOOS, JR domains, the percentage of patients who underwent THA who attained an MCID ranged from 91% to 95% using the distributionbased method, and it ranged from 67% to 92% using the anchor-based method. Furthermore, 67% to 85% of these patients attained an anchor-based substantial clinical benefit (Table 4) . More patients achieved a distributionbased MCID compared with those who achieved an anchor-based MCID. As expected, more patients attained an anchor-based MCID compared with those who got a substantial clinical benefit for the symptoms and ADL domains and for the HOOS, JR. For the pain domain, an equal number of patients obtained an anchor-based MCID and a substantial clinical benefit. For the QOL domain, the percentage of patients who attained a distribution-based MCID was equal to the proportion who achieved an anchor-based MCID. Across KOOS domains and the KOOS, JR, the percentage of patients undergoing TKA who achieved an MCID ranged from 77% to 91% using the distributionbased method; it ranged from 76% to 81% using the anchor-based method. In addition, 60% to 78% achieved an anchor-based substantial clinical benefit (Table 4) . More patients achieved a distribution-based MCID than an anchor-based MCID, and more patients attained an anchorbased MCID than a substantial clinical benefit for the pain and QOL domains and the HOOS, JR. For the symptoms domain, fewer patients attained a distribution-based MCID than achieved an anchor-based MCID. For the ADL domain, fewer patients achieved an anchor-based MCID than a substantial clinical benefit.
Discussion
The potential utility of PROMs is increasingly being recognized for the assessment of care delivery and care quality, but an adequate understanding how best to measure MDC, MCID, and substantial clinical benefit for jointspecific PROMs such as HOOS and KOOS has not been adequately established. We performed a comprehensive evaluation of the properties of the MCID and substantial clinical benefit for the HOOS, KOOS, and JR versions within a large CJR-eligible Medicare population. Consistent with previous reports, we found large variations in calculated MDCs and MCIDs depending on the methods used and assumptions made [9, 40] . Furthermore, highly variable percentages of patients achieved these thresholds depending on the methodology and the domain being evaluated. Critically, we found that MCIDs calculated using the distribution-based method are smaller than the corresponding MDCs, suggesting that these MCIDs are not valid estimates and may overestimate clinical benefit. Clinicians and policymakers should consider these findings in the process of developing an appropriate method to use HOOS, KOOS, and their JR versions to gauge patients' clinical improvement, to assess quality standards for public reporting, or to determine the appropriateness of procedures.
Limitations
There are some limitations to our study. The generalizability of our study sample is one potential limitation. Our study sample was from a single, high-volume institution, which may not be nationally representative. As an urban, tertiary care center, our institution receives referrals from near and far. Our population may be more economically advantaged than Medicare cohorts recruited at smaller hospitals in less urban areas. The followup period we chose is another potential limitation. The MDCs, MCIDs, and substantial clinical benefits reported in this study are based on a 2-year followup, and although they are likely comparable to those calculated using 1-year followup [38] , they may not be generalizable to those calculated using shorter followup [14, 15] . Like with any study requiring patient followup with PROMs, our completion rates must be sufficiently robust to minimize potential reporting bias. Although the study patients included in this analysis represent a minority of our Medicare patients, we had to make several judgments regarding who was eligible for followup. Patients undergoing surgery revision or an additional primary joint replacement before their 2-year followup were excluded, because it would be impossible to know whether the PROM scores reported at 2 years were influenced by their additional surgery. Therefore, we were limited to patients who did not have additional arthroplasty before their 2-year followup. Furthermore, the anchor-based approach is only as good as the anchor used. We have previously used our HSS Satisfaction Survey QOL question as an anchor for a study assessing factors associated with satisfaction after TKA [19] . That study population included all primary TKAs rather than only Medicare patients and the MCIDs were calculated for the WOMAC rather than the KOOS. We are currently working with Outcomes Measures in Rheumatology (OMERACT; https://omeract.org/) researchers to determine whether the HSS Satisfaction Survey would be a valid outcome measure in the satisfaction domain for TKA and THA.
Validity of MCID Estimates
We assessed the validity of estimates for MCID calculated using distribution-and anchor-based methods by determining whether they exceeded the MDC for the HOOS and KOOS domains, the HOOS, JR, and the KOOS, JR among patients who underwent THA or TKA. The MDC measures the precision of the selected PROM. It reflects the expected variability range if all responses were error-free. Hence, to be valid, MCIDs and substantial clinical benefits must exceed the MDC. On principle, the anchor-based ROC MCID may be considered superior to a distributionbased MCID because it relies on patient-reported improvements rather than an arbitrary sample distribution [20] . In this study, we demonstrated that the MCIDs calculated using the distribution-based approach were less than the MDC80, 90, and 95 for every domain as well as the JR versions, whereas anchor-based MCIDs exceed the MDC95 in seven of 10 domains, MDC90 in eight of 10, and MDC80 in nine of 10 (Table 3) .
Although the values for the distribution-based MCIDs we reported for HOOS/KOOS are similar to those noted by other researchers [3, 4] , the MDCs we described differed [26] . The KOOS MDC90s in this study (12-13 points) were substantially smaller than those from another recent study, which found MDC90s of 17 to 22 [26] . These differences can be explained by differences in sample size between the studies; our analysis was based on 2630 patients, whereas the other was based on 50 patients. Other investigators have also reported anchor-based MCIDs for the KOOS [22] and the HOOS [30] consistent with those we reported here, with one exception: the HOOS QOL domain. Paulsen et al. [30] reported an MCID of 19, whereas ours was 13. This may reflect cultural differences between study cohorts. The Paulsen cohort is based in Denmark, which was ranked the happiest country on earth in 2016 compared with the United States, which was ranked 13th [13] .
Substantial Clinical Benefit Thresholds
In this study, we determined the thresholds for a substantial clinical benefit for the HOOS/KOOS domains and the HOOS/KOOS, JR among patients who underwent THA or TKA. The substantial clinical benefits for all relevant domains were uniformly large and larger for the HOOS (mean 25) than the KOOS (mean 20). This is unsurprising because THA is generally considered a more successful procedure than TKA [5, 10] . As expected, the substantial clinical benefit exceeded the MDC at all degrees of certainty (80%-95%). Substantial clinical benefit also exceeded MCID in all but two domains: HOOS symptoms and KOOS ADL. In both cases, the substantial clinical benefit was roughly equivalent to the ROC MCID. In all analyses, the MDCs, MCIDs, and substantial clinical benefits for the HOOS, JR and KOOS, JR were smaller than the equivalent measurements for the HOOS and KOOS domains. This likely reflects that activities queried on the JR surveys are universal movements, resulting in less variability resulting from health literacy or variations in patient behavior [16, 17, 33] . This represents the first assessment of the MDC, MCID, and substantial clinical benefit for the JR versions to our knowledge, so no comparison to other studies is possible.
Proportions of Patients Achieving MCID and SCB
We assessed how many patients who underwent THA and TKA achieved an MCID for the HOOS/KOOS domains and HOOS/KOOS, JR based on distribution-based and anchor-based methods. In addition, we examined how many patients achieved substantial clinical benefit with the Volume 476, Number 12 anchor-based method. Overall, the percentage of patients who achieved MCID and a substantial clinical benefit after THA and TKA in our cohort was high, consistent with other measures such as patient satisfaction, which reflects the effectiveness of these procedures [6, 10, 18, 27] . The percentage of patients who achieved an MCID based on the distribution-based approach was generally greater than that of the corresponding anchor-based estimates (Table 4) . That all MCIDs for the distribution-based approach exceeded the corresponding MDCs (Table 3) suggests that the distribution-based approach overestimates the percentage of patients who achieve an MCID. Additionally, the proportion achieving substantial clinical benefit was lower than those achieving MCID for all domains except HOOS pain and KOOS ADL.
When using PROMs for clinical evaluation, changes in patients' scores that are lower than the MCID imply treatment failure, whereas those falling between the MCID and substantial clinical benefit indicate changes that were apparent to patients with only those exceeding the substantial clinical benefit signifying success. Consequently, it is critically important that estimates of MCIDs and substantial clinical benefits be reliable and valid. Although distribution-based MCIDs can be readily calculated from any data set with PROMs collected at different points, ease of calculation does not beget valid estimates, as we demonstrated here. Furthermore, distribution-based MCIDs may not be comparable across cohorts and hence preclude comparisons. Anchor-based MCIDs have greater face and construct validity, allowing for more accurate estimates within and across cohorts. Anchors are less readily available, and hence MCIDs based on anchors are less frequently reported, but our findings argue for routinely collecting them. Additional research is needed to confirm the results we report here. In particular, adequate anchors should be investigated to confirm the superiority of anchorbased MCIDs. Such studies will help our field to reach consensus on the standard definitions for valid and reliable MCIDs and substantial clinical benefits so that they can be applied as reliable and validated measures to guide clinical care, assess provider performance, and determine appropriateness of care.
